JK07 in Subjects with Heart Failure with Reduced Ejection Fraction (HFrEF)
Brief description of study
Patients with Heart Failure with Reduced Ejection Fraction (HFrEF) will be invited to participate in this study.
HFrEF is a condition in which the heart pumps a lower than normal amount of blood. The purpose of this study is to evaluate the safety and activity of the investigational product in subjects with heart HFrEF. This study is a “first-in-human” study of the protein JK07 and will determine if, and at what dose, this product is safe and tolerable, how long it stays in your body, and whether it has any effect on your heart function.
Participants will be asked to complete the following research procedures which are not part of your standard of care:
Vital Sign Measurements, Electrocardiograms, Echocardiograms, Study Drug Administration, Blood Draws, Heart Monitoring Devices, and Physical Examinations
Participation will last about 6 months (approximately 15 visits), including a 2-day hospital stay when receiving the investigational product, with 10 additional follow-up visits.
There will be no cost for these research visits and the study drug will be provided free of charge.
Recruitment will be conducted through the heart failure clinic at Penn Medicine
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
heart failure,reduced ejection fraction
-
Age: Between 18 Years - 80 Years
-
Gender: All
Updated on
11 Jun 2021.
Study ID: 843290
